Literature DB >> 32197268

The phase 3 pediatric anticoagulant era.

Neil A Goldenberg1, Brian R Branchford2.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32197268      PMCID： PMC7019189          DOI： 10.1182/blood.2019004340

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

Review 1.  Definition of post-thrombotic syndrome following lower extremity deep venous thrombosis and standardization of outcome measurement in pediatric clinical investigations.

Authors:  N A Goldenberg; L R Brandão; J Journeycake; S R Kahn; P Monagle; S Revel-vilk; A Sharathkumar; A K C Chan
Journal:  J Thromb Haemost       Date:  2012-03       Impact factor: 5.824

2.  Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children.

Authors:  L G Mitchell; N A Goldenberg; C Male; G Kenet; P Monagle; U Nowak-Göttl
Journal:  J Thromb Haemost       Date:  2011-09       Impact factor: 5.824

Review 3.  Standardization of post-thrombotic syndrome definition and outcome assessment following upper venous system thrombosis in pediatric practice.

Authors:  S Revel-Vilk; L R Brandão; J Journeycake; N A Goldenberg; A Goldenberg; P Monagle; A Sharathkumar; A K C Chan
Journal:  J Thromb Haemost       Date:  2012-10       Impact factor: 5.824

4.  Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.

Authors:  Christoph Male; Anthonie W A Lensing; Joseph S Palumbo; Riten Kumar; Ildar Nurmeev; Kerry Hege; Damien Bonnet; Philip Connor; Hélène L Hooimeijer; Marcela Torres; Anthony K C Chan; Gili Kenet; Susanne Holzhauer; Amparo Santamaría; Pascal Amedro; Elizabeth Chalmers; Paolo Simioni; Rukhmi V Bhat; Donald L Yee; Olga Lvova; Jan Beyer-Westendorf; Tina T Biss; Ida Martinelli; Paola Saracco; Marjolein Peters; Krisztián Kállay; Cynthia A Gauger; M Patricia Massicotte; Guy Young; Akos F Pap; Madhurima Majumder; William T Smith; Jürgen F Heubach; Scott D Berkowitz; Kirstin Thelen; Dagmar Kubitza; Mark Crowther; Martin H Prins; Paul Monagle
Journal:  Lancet Haematol       Date:  2019-11-05       Impact factor: 18.959

5.  Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.

Authors:  Leonardo R Brandão; Manuela Albisetti; Jacqueline Halton; Lisa Bomgaars; Elizabeth Chalmers; Lesley G Mitchell; Ildar Nurmeev; Pavel Svirin; Tomas Kuhn; Ondrej Zapletal; Igor Tartakovsky; Monika Simetzberger; Fenglei Huang; Zhichao Sun; Jörg Kreuzer; Savion Gropper; Martina Brueckmann; Matteo Luciani
Journal:  Blood       Date:  2020-02-13       Impact factor: 22.113

6.  Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings.

Authors:  N A Goldenberg; T Abshire; P J Blatchford; L Z Fenton; J L Halperin; W R Hiatt; C M Kessler; J M Kittelson; M J Manco-Johnson; A C Spyropoulos; P G Steg; N V Stence; A G G Turpie; S Schulman
Journal:  J Thromb Haemost       Date:  2015-08-11       Impact factor: 5.824

Review 7.  Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.

Authors:  Virginie Dufrost; Jessie Risse; Tatiana Reshetnyak; Maria Satybaldyeva; Yao Du; Xin-Xin Yan; Stella Salta; Grigorios Gerotziafas; Zhi-Cheng Jing; Ismaël Elalamy; Denis Wahl; Stéphane Zuily
Journal:  Autoimmun Rev       Date:  2018-08-11       Impact factor: 9.754

8.  Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.

Authors:  Vittorio Pengo; Gentian Denas; Giacomo Zoppellaro; Seena Padayattil Jose; Ariela Hoxha; Amelia Ruffatti; Laura Andreoli; Angela Tincani; Caterina Cenci; Domenico Prisco; Tiziana Fierro; Paolo Gresele; Arturo Cafolla; Valeria De Micheli; Angelo Ghirarduzzi; Alberto Tosetto; Anna Falanga; Ida Martinelli; Sophie Testa; Doris Barcellona; Maria Gerosa; Alessandra Banzato
Journal:  Blood       Date:  2018-07-12       Impact factor: 22.113
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.